TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4018499

Group type: EXPERIMENTAL
Intervention: Cimetidine bolus administration (up to 300 mg every 6 h, 1200 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cimetidine primed infusion (up to 50 mg/h, 1200 mg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cimetidine (both methods)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cimetidine infusion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cimetidine (therapeutic levels)
Number of subjects: 23
Study: 29036480

Group type: EXPERIMENTAL
Intervention: Mandible advanced device (MAD) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group OSAHS (induced OSAHS without treatment)
Number of subjects: 30
Study: 27343983

Group type: EXPERIMENTAL
Intervention: Cell culture-derived trivalent influenza vaccine (TIVc)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Egg-derived trivalent influenza vaccine (TIV)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Both TIVc and TIV
Number of subjects: 430
Study: 25045360

Group type: EXPERIMENTAL
Intervention: Google search queries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-based combined symptom medication score
Number of subjects: 0
Study: 21864865

Group type: COMPARATOR
Intervention: Exercise with placebo (EX + PL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise with phytoestrogens (EX + PHY)
Number of subjects: 52
Study: 20159380

Group type: EXPERIMENTAL
Intervention: Functional microarray (FMA) applied to one forearm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham device applied to the other forearm
Number of subjects: 25
Study: 18826358

Group type: EXPERIMENTAL
Intervention: Cyclosporine (1.25-5 mg/kg/day) administered intravenously, initiated within 8 hours of injury, in 2 divided doses or continuous infusion over 72 hours.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment, initiated within 8 hours of injury.
Number of subjects: 40
Study: 16193496

Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) 0.31 mg
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) 0.63 mg
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Racemic albuterol (RAC) 1.25 mg (for children <33 lb)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Racemic albuterol (RAC) 2.5 mg (for children >/=33 lb)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 211
Study: 12421065

Group type: EXPERIMENTAL
Intervention: Binocular viewing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monocular viewing
Number of subjects: 0
Study: 10359887

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate powder, 500 microgram, twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7677297

Group type: EXPERIMENTAL
Intervention: Resistance to thyroid hormone
Number of subjects: 104
Study: 2371802

Group type: EXPERIMENTAL
Intervention: Propofol in emulsion (Diprivan) - bolus of 2 mg/kg followed by infusion of 6 mg/kg/h for one hour.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralipid 10% - bolus of 0.2 mg/kg followed by infusion of 0.6 ml/kg/h for one hour.
Number of subjects: 20
Study: 6164204

Group type: EXPERIMENTAL
Intervention: Dihydroergotamin and low-dose heparin (DHEH)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Sulphated polysaccharid (PZ68B)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 357
Study: 31404668

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1758

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg (more than 12 months exposure)
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Placebo (more than 12 months exposure)
Number of subjects: 1758
Study: 31082305

Group type: EXPERIMENTAL
Intervention: UAV-assisted scouting using multispectral imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional scouting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UAV-assisted scouting
Number of subjects: 0
Study: 27845858

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25392071

Group type: EXPERIMENTAL
Intervention: Atorvastatin (n=255)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Pravastatin (n=253)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 508
Study: 23708038

Group type: EXPERIMENTAL
Intervention: Miniscrew
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional utility arch
Number of subjects: 20
Study: 21250762

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19548407

Group type: EXPERIMENTAL
Intervention: Reinforced adjustable mandibular advancement appliance (MAA) at 25% protrusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reinforced adjustable mandibular advancement appliance (MAA) at 75% protrusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mandibular occlusal splint (MOS)
Number of subjects: 12
Study: 18260979

Group type: EXPERIMENTAL
Intervention: MMP-9/TIMP-1 ratio in patients with volume overload
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMP-1 levels in patients with pressure overload
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMP-9/TIMP-1 coefficient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIMP-1 content in patients with aortic stenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentration of MMP-9 and MMP-9/TIMP-1 ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum levels of MMP-9 and TIMP-1
Number of subjects: 0
Study: 12955096

Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide administered subcutaneously at 2245
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11449530

Group type: EXPERIMENTAL
Intervention: Beclomethasone (Ibec) - 2 puffs/12 hr, 100 micrograms per puff
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Beclomethasone-salmeterol (Ibe + Isal) - Beclomethasone 2 puffs/12 hr, 100 micrograms per puff and Salmeterol 2 puffs/12 hr, 25 micrograms per puff
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Beclomethasone (Ibec)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Beclomethasone-salmeterol (Ibe + Isal)
Number of subjects: 29
Study: 11832140

Group type: EXPERIMENTAL
Intervention: Anisodamine (T group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No Anisodamine (C group)
Number of subjects: 42
Study: 8880076

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1839434

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study: 6841391

Group type: EXPERIMENTAL
Intervention: Anaesthesia with induced hypotension using sodium nitroprusside and trimetaphan
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard anaesthesia without induced hypotension
Number of subjects: 44
Study: 29723124

Group type: EXPERIMENTAL
Intervention: Telerehabilitation assessment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 47
Study: 29622393

Group type: EXPERIMENTAL
Intervention: Educational intervention in the ED waiting room before seeing the emergency physician, followed by a 30-day telephone follow-up.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 94
Study: 26402918

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg, increased to 400 mg if uncontrolled after 2 weeks, with optional addition of another antihypertensive drug after 4 weeks (n=21)
Number of subjects: 35
Study: 24821628

Group type: EXPERIMENTAL
Intervention: L-bent-level gesture
Number of subjects: 420

Group type: COMPARATOR
Intervention: Baseline (no gesture)
Number of subjects: 420
Study: 22311378

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Kava (180 mg of kavalactones)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20424465

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 10 Hz and 90% motor threshold intensity
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 10
Study: 18594000

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (260 mg/m² as a 30-minute infusion)
Number of subjects: 17

Group type: COMPARATOR
Intervention: sb-paclitaxel (175 mg/m² as a 3-hour infusion)
Number of subjects: 17
Study: 15959923

Group type: EXPERIMENTAL
Intervention: Primary astrocytomas
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Meningiomas
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recurrent astrocytomas
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recurrent low-grade astrocytomas
Number of subjects: 46
Study: 11952043

Group type: EXPERIMENTAL
Intervention: MRI-T2 signal intensity (SI) assessment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MRI-T2 pattern assessment
Number of subjects: 39
Study: 10495459

Group type: EXPERIMENTAL
Intervention: Primary care service delivered by one type of medical doctor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary care service delivered by another type of medical doctor
Number of subjects: 0
Study: 7721556

Group type: EXPERIMENTAL
Intervention: Daily baths in the Dead Sea (Group 1, n = 9)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daily sulphur baths (Group 2, n = 9)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of daily Dead Sea bathing and sulphur baths (Group 3, n = 10)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group 4, n = 8)
Number of subjects: 36
Study: 2116440

Group type: EXPERIMENTAL
Intervention: GHRH 125 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH 250 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH 500 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH 750 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH 1000 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30378759

Group type: EXPERIMENTAL
Intervention: PLGM threshold at 90 mg/dL during exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PLGM threshold at 70 mg/dL during exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: PLGM system (both thresholds)
Number of subjects: 34
Study: 29718777

Group type: EXPERIMENTAL
Intervention: Task-Specific Balance Training (TSBT), 60 minutes per session, three times a week for 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Task-Specific Balance Training (TSBT)
Number of subjects: 100
Study: 26961741

Group type: EXPERIMENTAL
Intervention: Standardized exercise program consisting of muscle strength exercises and endurance training.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard group (control).
Number of subjects: 107
Study: 25310120

Group type: EXPERIMENTAL
Intervention: POC Plus (point-of-care CD4 devices and related counseling support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (routine, laboratory-based CD4 testing)
Number of subjects: 0
Study: 22649214

Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 294
Study: 20181504

Group type: EXPERIMENTAL
Intervention: Motor skill training involving isolated voluntary contractions of transversus abdominis (TrA) for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-paced walking exercise for 2 weeks
Number of subjects: 20
Study: 18175604

Group type: EXPERIMENTAL
Intervention: Randomization in experimental design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15608053

Group type: COMPARATOR
Intervention: Triple therapy (zidovudine/lamivudine and efavirenz)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (zidovudine/lamivudine/abacavir and efavirenz)
Number of subjects: 53
Study: 12145057

Group type: COMPARATOR
Intervention: IV atropine 10 microg/kg
Number of subjects: 61

Group type: COMPARATOR
Intervention: IV atropine 20 microg/kg
Number of subjects: 61
Study: 10532982

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2B (3 x 10(6) IU per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study: 8829846

Group type: EXPERIMENTAL
Intervention: Nonselective angiography
Number of subjects: 56

Group type: COMPARATOR
Intervention: Selective angiography
Number of subjects: 56
Study: 2108751

Group type: EXPERIMENTAL
Intervention: Erythropoietin to achieve a haemoglobin concentration of 95‐110 g/l (n = 40)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Erythropoietin to achieve a haemoglobin concentration of 115‐130 g/l (n = 38)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 118
Study: 7352279

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30968588

Group type: EXPERIMENTAL
Intervention: Oral NEPA (netupitant-palonosetron 300/0.50 mg)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Oral palonosetron 0.50 mg
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Oral aprepitant 125 mg day 1, 80 mg days 2-3/palonosetron 0.50 mg
Number of subjects: 1862
Study: 27707593

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Secukinumab (both doses)
Number of subjects: 205
Study: 26486525

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (IAD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (CAD)
Number of subjects: 114
Study: 25622671

Group type: EXPERIMENTAL
Intervention: 0.50 µg calcitriol daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (original treatment regimen)
Number of subjects: 164
Study: 21385791

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 41778
Study: 19717850

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 3690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3690
Study: 15698698

Group type: EXPERIMENTAL
Intervention: C‐Breeze collar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Miami J collar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: XTW collar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspen collar
Number of subjects: 20
Study: 12833245

Group type: EXPERIMENTAL
Intervention: Intravenous pulses of methylprednisolone (MEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gold standard dose of 1 g/day for 3 consecutive days of MEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses of MEP
Number of subjects: 0
Study: 10036892

Group type: EXPERIMENTAL
Intervention: Propofol injected through a central venous catheter (group A, n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B, n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C, n = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propofol injected through a central venous catheter (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C)
Number of subjects: 39
Study: 8694599

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits (HBC) with lower anticoagulation therapy (activated clotting time > 280 seconds)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits (HBC) with lower anticoagulation therapy
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional, nonheparin-bonded circuits with full anticoagulation therapy (activated clotting time > 480 seconds)
Number of subjects: 234
Study: 1831686

Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with three-monthly scale and polish and reinforcement of oral hygiene instruction (Group 3)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with one-monthly input from a dental hygienist (Group 4)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Daily supervised toothbrushing without additional treatment (Control group)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with three-monthly scale and polish (Group 3)
Number of subjects: 382
Study: 7159690

Group type: EXPERIMENTAL
Intervention: Combination tablet containing 25 mg bemetizide and 50 mg triamterene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bemetizide alone (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamterene alone (50 mg)
Number of subjects: 0
Study: 31033867

Group type: EXPERIMENTAL
Intervention: Sodium intake of 2,400 mg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sodium intake of 1,500 mg per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unrestricted sodium intake (control group)
Number of subjects: 42
Study: 26485692

Group type: EXPERIMENTAL
Intervention: Foot Method (FM)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Hand Method (HM)
Number of subjects: 105
Study: 26010521

Group type: EXPERIMENTAL
Intervention: 21‐mg transdermal nicotine patch
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Number of subjects: 32

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 32
Study: 23250992

Group type: EXPERIMENTAL
Intervention: CR orientation appointment within 10 days (early)
Number of subjects: 148

Group type: COMPARATOR
Intervention: CR orientation appointment at 35 days (standard)
Number of subjects: 148
Study: 22015074

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30-minute intravenous infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 8
Study: 18091545

Group type: EXPERIMENTAL
Intervention: Combination therapy with meropenem (1 g every 8 hrs) and ciprofloxacin (400 mg every 12 hrs)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Monotherapy with meropenem alone
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 740

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 740
Study: 17146023

Group type: EXPERIMENTAL
Intervention: Life skills-oriented physical activity intervention in physical education class
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard physical education class (control)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Life skills-oriented physical activity intervention
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study: 15019339

Group type: EXPERIMENTAL
Intervention: Surgery performed by ophthalmologists
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Surgery performed by integrated eye care workers (IECWs)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Overall recurrence
Number of subjects: 982
Study: 11320045

Group type: EXPERIMENTAL
Intervention: Etamsylate
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study: 9203645

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 554
Study: 8203833

Group type: EXPERIMENTAL
Intervention: Cefepime (CP; 2.0 g IV every 12 h)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ceftazidime (CZ; 2.0 g IV every 8 h)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cefepime (CP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ceftazidime (CZ)
Number of subjects: 133
Study: 3295623

Group type: EXPERIMENTAL
Intervention: Treatment arm 1
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Treatment arm 2
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 31863557

Group type: EXPERIMENTAL
Intervention: Metformin (1450 ± 550 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29962867

Group type: EXPERIMENTAL
Intervention: Covered metallic ureteral stent (CMS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Double-J ureteral stent (DJS)
Number of subjects: 19
Study: 27631145

Group type: EXPERIMENTAL
Intervention: Culturally sensitive collaborative care for depression
Number of subjects: 190
Study: 24237962

Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance and strength training (4 sessions per week)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acute endurance workload of 45 min at 70% of VO(2max)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance and strength training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pre-diabetes subjects
Number of subjects: 26
Study: 22579509

Group type: EXPERIMENTAL
Intervention: Active (positive) computer-based attentional bias modification (ABM) with face-based stimuli
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo computer-based attentional bias modification (ABM) with word-based stimuli
Number of subjects: 61
Study: 19889408

Group type: EXPERIMENTAL
Intervention: Simulator training (16 hours)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient-based training (control)
Number of subjects: 36
Study: 18188742

Group type: EXPERIMENTAL
Intervention: X-Pack Program (moderately intensive, E-mail-based intervention)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clearing the Air group (less-intensive program aimed at a general adult audience)
Number of subjects: 83
Study: 16489197

Group type: EXPERIMENTAL
Intervention: Uvex plastic mask system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Finesse Frame with Ultraplast System
Number of subjects: 20